Literature DB >> 15193739

Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection.

Tsukasa Uno1, Norio Yasui-Furukori, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi.   

Abstract

A simple and sensitive method was developed for determination of fexofenadine by liquid chromatography with fluorescence detection. Fexofenadine in human plasma was extracted on a C18 bonded-phase extraction cartridge. The mobile phases were: (A) 0.05 M KH2PO4 buffer/acetonitrile/methanol (60:35:10, v/v/v) and (B) 0.05 M KH2PO4 buffer/acetonitrile (40:60, v/v). Chromatographic separation was achieved on an ODS-80A column (150 mm x 4.6 mm i.d., particle size 5 microm) using a linear gradient from A to B in 10 min. The peak was detected using a fluorescence detector set at Ex 220 nm and Em 290 nm, and the total time for a chromatographic separation was approximately 17 min. The validated quantitation ranges of this method were 1.0-500 ng/ml with coefficients of variation of 0.6-9.1%. Mean recoveries were 72.8-76.7% with coefficients of variation of 2.7-5.8%. This method is successfully applicable for therapeutic drug monitoring in patients treated with clinical doses of fexofenadine and for analyses within pharmacokinetic studies. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193739     DOI: 10.1016/j.jpba.2004.02.036

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Validated spectroflurimetric determination of some H1 receptor antagonist drugs in pharmaceutical preparations through charge transfer complexation.

Authors:  Mohie K Sharaf el-Din; Fawzia Ibrahim; Manal I Eid; Mary E K Wahba
Journal:  J Fluoresc       Date:  2011-08-10       Impact factor: 2.217

2.  Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

3.  Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry.

Authors:  Colleen A Flynn; Yazen Alnouti; Gregory A Reed
Journal:  Rapid Commun Mass Spectrom       Date:  2011-08-30       Impact factor: 2.419

4.  Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

5.  Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.

Authors:  Melonie L Stanton; Melanie S Joy; Reginald F Frye
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-12-24       Impact factor: 3.205

6.  Stability-indicating HPLC Method for Simultaneous Determination of Montelukast and Fexofenadine Hydrochloride.

Authors:  Mona Pankhaniya; Parula Patel; J S Shah
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

7.  Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates-Fexofenadine in Taiwanese?

Authors:  Y A Chen; C H Juan; K Y Hsu
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

8.  The Pharmacokinetic Exposure to Fexofenadine is Volume-Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice.

Authors:  J Luo; H Imai; T Ohyama; S Hashimoto; T Hasunuma; Y Inoue; T Kotegawa; K Ohashi; N Uemura
Journal:  Clin Transl Sci       Date:  2016-05-19       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.